View More Recent Stories

Jul 17, 2023 04:01PM Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)
May 31, 2023 08:00AM Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference
May 15, 2023 04:01PM Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 2, 2023 08:00AM Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension
Mar 15, 2023 04:01PM Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Mar 6, 2023 05:53AM Mineralys Therapeutics (MLYS) Reports Positive Lorundrostat Results from the Phase 2 Target-HTN Trial
Mar 4, 2023 04:30PM Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC
View More Recent Stories